• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    9/20/23 1:31:09 PM ET
    $BFLY
    $BIOL
    $BJDX
    $EVAX
    Medical Electronics
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BFLY alert in real time by email

    Gainers

    • MSP Recovery (NASDAQ:LIFW) stock moved upwards by 118.1% to $0.2 during Wednesday's regular session. MSP Recovery's stock is trading at a volume of 436.7 million shares as of 13:30 EST. This is 3233.0% of its average full-day volume over the last 100 days. The company's market cap stands at $67.9 million.
    • Fresh Tracks Therapeutics (NASDAQ:FRTX) shares rose 54.22% to $0.9. The current volume of 9.9 million shares is 1515.7% of Fresh Tracks Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $5.3 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 49.01% to $4.62. Trading volume for this security as of 13:30 EST is 33.6 million, which is 5674.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.7 million.
    • Evaxion Biotech (NASDAQ:EVAX) shares rose 36.51% to $0.66. Trading volume for Evaxion Biotech's stock is 1.3 million as of 13:30 EST. This is 1998.7% of its average full-day volume over the last 100 days. The company's market cap stands at $18.1 million.
    • Histogen (NASDAQ:HSTO) stock increased by 31.87% to $0.52. Trading volume for this security as of 13:30 EST is 6.3 million, which is 8969.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock rose 28.95% to $0.68. As of 13:30 EST, this security is trading at a volume of 18.5 million shares, making up 7419.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.3 million.

    Losers

    • Seelos Therapeutics (NASDAQ:SEEL) stock declined by 71.8% to $0.28 during Wednesday's regular session. Trading volume for this security as of 13:30 EST is 40.6 million, which is 4394.8% of its average full-day volume over the last 100 days. The company's market cap stands at $36.0 million.
    • ARS Pharmaceuticals (NASDAQ:SPRY) stock decreased by 56.25% to $2.89. The current volume of 15.6 million shares is 2778.3% of ARS Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $276.1 million.
    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares fell 16.67% to $0.0. As of 13:30 EST, Longeveron Inc. - Subscription Right's stock is trading at a volume of 2.8 million, which is 350.2% of its average full-day volume over the last 100 days.
    • Biolase (NASDAQ:BIOL) shares decreased by 14.4% to $1.79. The current volume of 684.2K shares is 249.5% of Biolase's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $1.8 million.
    • Butterfly Network (NYSE:BFLY) shares fell 14.39% to $1.19. The current volume of 4.5 million shares is 246.9% of Butterfly Network's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $245.8 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) shares declined by 12.47% to $0.77. Sonoma Pharmaceuticals's stock is trading at a volume of 63.1K shares as of 13:30 EST. This is 228.1% of its average full-day volume over the last 100 days. The company's market cap stands at $3.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BFLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFLY
    $BIOL
    $BJDX
    $EVAX

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    ARS Pharmaceuticals Inc.
    $SPRY
    11/4/2025$30.00Buy
    Roth Capital
    ARS Pharmaceuticals Inc.
    $SPRY
    9/4/2025$40.00Buy
    Roth Capital
    Butterfly Network Inc.
    $BFLY
    8/1/2025Outperform → Perform
    Oppenheimer
    Butterfly Network Inc.
    $BFLY
    7/1/2025$3.00Buy
    Craig Hallum
    Butterfly Network Inc.
    $BFLY
    3/17/2025Outperform
    William Blair
    ARS Pharmaceuticals Inc.
    $SPRY
    3/7/2025$30.00Sector Outperform
    Scotiabank
    ARS Pharmaceuticals Inc.
    $SPRY
    2/10/2025$40.00Outperform
    Oppenheimer
    More analyst ratings

    $BFLY
    $BIOL
    $BJDX
    $EVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital resumed coverage on ARS Pharmaceuticals with a new price target

    Roth Capital resumed coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $30.00

    11/4/25 8:07:28 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on ARS Pharmaceuticals with a new price target

    Roth Capital initiated coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/4/25 7:57:34 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFLY
    $BIOL
    $BJDX
    $EVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Rono Birgitte

    3/A - Evaxion A/S (0001828253) (Issuer)

    3/27/26 5:10:17 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 3 filed by new insider Schmidt Thomas Frederik

    3/A - Evaxion A/S (0001828253) (Issuer)

    3/27/26 5:09:43 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 3 filed by new insider Prego Roberto

    3/A - Evaxion A/S (0001828253) (Issuer)

    3/27/26 5:09:14 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFLY
    $BIOL
    $BJDX
    $EVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

    Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range to access a needle-free epinephrine without age restrictions Updated labeling recommends storage in blister packaging or a neffy carrying case; ARS Pharma currently makes carrying cases available and will include one with each prescription beginning this summer SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that cou

    3/27/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Notice to convene Evaxion's Annual General Meeting

    COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET. The meeting will be held at the company's offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. The agenda and proposals can be found on Evaxion's website, along with other materials: www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/ Contact information Evaxion A/SMads KronborgVice President, Investor Relations & Communication+45 53 54 82 96 [email protected] About Evaxion Evaxion is a pione

    3/19/26 9:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to present new data at AACR Annual Meeting

    Two abstracts accepted for presentationOne abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01Another abstract on the use of Evaxion's AI-Immunology™ platform in developing a personalized cancer vaccine strategy for glioblastoma (brain cancer)Evaxion will also participate in the AACR Oncology Industry Partnering event ahead of the annual meeting COPENHAGEN, Denmark, March 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces two abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting ta

    3/17/26 4:30:00 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFLY
    $BIOL
    $BJDX
    $EVAX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Butterfly Network Inc.

    SCHEDULE 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

    3/26/26 4:40:28 PM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form SCHEDULE 13G filed by ARS Pharmaceuticals Inc.

    SCHEDULE 13G - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

    3/24/26 4:18:45 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/19/26 9:10:04 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFLY
    $BIOL
    $BJDX
    $EVAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $64,471 worth of shares (21,370 units at $3.02) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/15/25 6:20:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $4,652,773 worth of shares (1,558,541 units at $2.99) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/5/25 5:40:49 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    $BIOL
    $BJDX
    $EVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFLY
    $BIOL
    $BJDX
    $EVAX
    Financials

    Live finance-specific insights

    View All

    ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

    neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for t

    3/9/26 6:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to announce business update and full year 2025 financial results on March 5, 2026

    COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces

    3/2/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFLY
    $BIOL
    $BJDX
    $EVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    11/14/24 7:32:44 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care